372 results about "Antibody fragments" patented technology

Antibodies and antibody fragments that bind to polyfluoroalkyl and perfluoroalkyl species (PFAS) are described for use in biosensors for detecting PFAS compounds in environmental samples. A detector comprising the biosensor and a kit for use with the detector are also described.

The present invention relates to a novel antibody and antibody fragment specifically binding to Nectin-4, and a composition containing the antibody or the antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell containing same, and a related use. Further, the present invention relates to therapeutic and diagnostic uses of the antibody and the antibody fragment.

The present invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents to deliver pharmaceutical compounds into or through cells during receptor-mediated endocytosis and / or transendocytosis processes. As transferrin receptors are also present in the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase delivery of pharmaceutical compounds to the central nervous system.

The present invention relates to antibodies, and fragments thereof, that bind and inhibit CD73. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, e.g., a camptothecin cytotoxic molecule which is cell-permeable; as a second payload a topoisomerase I inhibitor which is not cell-permeable, e..g., a camptothecin cytotoxic molecule which is not cell-permeable; and as a as a third payload a toxin or a cytotoxin, e.g., an auristatin such asMMAE (Monomethyl auristatin E). Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

Provided herein is disclosure of a recombinant bifunctional protein or polypeptide capable of binding to a cell surface receptor for lysosome targeting that is made up of an N-glycosylated peptide comprising at least one N-glycan group and a protein of interest, or antibody or antibody fragment capable of binding to a protein of interest. Also provided herein are methods for producing said recombinant bifunctional protein. Also provided herein are methods for lysosomal degradation of a protein of interest comprising introducing to a cell the peptide sequence of the recombinant bifunctional protein.

The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15 / IL-15Rα Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.

The invention relates in one aspect to a computer-implemented method for predicting the binding of at least one protein of interest, preferably at least one receptor, antibody, antibody fragment or equivalents thereof, or DARPin, to a peptide of interest, comprising a. providing sequence and / or structural data of at least one reference peptide, optionally providing sequence and / or structural data of at least one HLA molecule and / or of at least one HLA-peptide complex (pHLA), and / or the at least one reference peptide presented within a pHLA complex, b. providing binding data, preferably comprising the dissociation constant (KD), of the at least one reference peptide and / or the at least one reference peptide presented within a HLA-peptide complex (pHLA) with at least one protein of interest, c. training a machine learning (ML)-based model or artificial intelligence (AI) based on the data provided in a. and the binding data provided in b., d. providing sequence and / or structural data of at least one peptide of interest, e. employing the machine learning (ML)- based model or artificial intelligence (AI) trained in c. to predict the binding or interaction properties of the at least one peptide of interest, preferably when presented within a pHLA complex, to the at least one protein of interest.

Surrogate co-receptors for T cells, including T cells expressing chimeric receptors comprising major histocompatibility molecules grafted onto T cell receptor molecules. The surrogate co-receptors feature a portion of CD8, wherein the Ig domains of CD8 are replaced with Ig domains that confer novel specificities (e.g. antibody Fv fragments specific for a target of interest.) The surrogate co-receptors may be used to help enhance CRMpMHC-CD3 signaling as part of a 5-module receptor system. The present invention also describes Lck fusions.

Provided and exemplified herein are antibodies and antibody fragments that bind an IgE constant domain.

The invention belongs to the technical field of biology, and particularly relates to a fusion protein and application thereof in competitive inhibition of MDM2 and further recovery of TP53 activity. The fusion protein provided by the invention comprises an antibody fragment, a modified progesterone receptor and an RING subunit of an antibody receptor Trim21 which are connected in sequence, has a composite structure of an antibody and a part of subunits of the Trim21, can specifically degrade a target protein, competitively inhibits MDM2 while degrading the target protein, further recovers the activity of a P53 gene, and has a good application prospect. The anti-tumor effect is also realized.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

The invention relates to an antibody or an antigen fragment of a targeted human CD7 and application of the antibody or the antigen fragment. The antibody and the CD7-CAR based on the antibody fragment have extremely strong affinity with a CD7 antigen molecule, and a blocking molecule containing the antibody can almost completely block the expression of the CD7 molecule on the cell surface without influencing the normal amplification of T cells, so that the self-killing of the CD7-CAR-T cells can be effectively avoided. The CD7-CAR-T cell constructed on the basis of the single-domain antibody of the targeted human source CD7 has a strong killing effect on a target cell.

The application discloses an antibody drug conjugate, which comprises the following formula 1: formula 1 wherein Ab is an antibody or antibody fragment for targeting Lewis Y, and j is 1-8, preferably 4-8. The antibody drug conjugate disclosed by the application can be combined with tumor cells expressing Lewis Y protein with high specificity, thereby achieving excellent killing effect on cells.

The present application relates to a novel antibody or antibody fragment thereof of interleukin-23 receptor, which can effectively bind IL-23R, block the binding of IL-23R and human IL-23 alpha / IL-12 beta heterodimer ligand, and has good application prospect. The antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises VH CDR1, VH CDR2 and VH CDR3, and the light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3, wherein VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 3, 13 or 23, VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 4, 14 or 24, VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 5, 15 or 25; VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, 18 or 28, VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, 19 or 29, and VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, 20 or 30.

A conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment that binds to human EpCAM protein, the IgG antibody or antibody fragment comprising a light chain variable region having three complementarity-determining regions L1, L2, and L3, and a heavy chain variable region having three complementarity-determining regions H1, H2, and H3; and at least one scFv antibody fragment that binds to a T lymphocyte protein linked to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.

Anti-CLEC12A polypeptides typically include an amino acid sequence having at least 90% amino acid similarity to SEQ ID NO: 14. In certain embodiments, the anti-CLEC12A polypeptides can be incorporated into an anti-CLEC12A biologic. In some of these embodiments, the anti-CLEC12A biologic can be a bispecific killer cell engager (BiKE), a trispecific killer cell engager (TriKE), a tetraspecific killer cell engager (TetraKE), a pentaspecific killer cell engager (PentaKE), a bispecific T cell engager (BiTE), a trispecific T cell engager (TriTE), a tetraspecific T cell engager (TetraTE), a pentaspecific T cell engager (PentaTE), a chimeric antigen receptor, a whole antibody, an antibody-drug conjugate (ADC) molecule, a targeted delivery construct, or a labeling construct.

A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.

The present disclosure provides conjugates comprising a targeting moiety, such as an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload) wherein the targeting moiety, such as an antibody, Fab fragment or ScFv, is conjugated to the lipid nanoparticle via a linker, and wherein the linker comprises an enzyme recognition sequence and a click product formed by a click reaction between a first click handle on the targeting moiety such as an antibody, Fab fragment or ScFv and a second click handle on the LNP.

The present disclosure describes proteins that specifically bind to human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include recombinant human anti-Sp17 IgG, which are suitable for use as therapeutic antibodies to treat cancers that express Sp17 ectopic. Other Sp17 binding proteins, including antibody fragments, antibody conjugates, and fusion proteins, are also described.

The present invention relates to an antibody or antibody fragment capable of binding to G protein alpha, a nucleic acid sequence encoding said antibody, a vector comprising said nucleic acid sequence, a cell comprising said vector or said nucleic acid sequence and a kit comprising: i) said antibody or antibody fragment or said composition and ii) a GTP source labeled with a member of a RET partner pair.

Provided and exemplified herein are antibodies and antibody fragments that bind OSMR.

Provided herein are bispecific antibodies and antibody fragments that bind to both human TNFRSF25 and Α4Β7. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- and Α4Β7-binding bispecific antibody.

The present invention relates to a monospecific or bispecific antibody, or an antibody fragment or fusion protein thereof, capable of binding to the VHL ligand VH032 (or derivative thereof) degrading moiety (degradation determinant) of a proteolytic targeting chimera (PROTAC), and optionally to a target protein. The invention also relates to complexes (PAX) of such antibodies, or antibody fragments or fusion proteins thereof, with PROTACS, as well as methods for their production, and their respective medical and non-medical uses.

The present disclosure provides methods for treating thyroid eye disease, comprising subcutaneously administering a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment to a patient in need of treatment. Also provided herein are pharmacologically active agents, compositions, methods, and / or administration schedules for the treatment of thyroid eye disease.

The present disclosure provides, among other things, antibodies and antibody fragments that bind to neonatal Fc receptor (FcRn). Pharmaceutical compositions comprising the engineered proteins disclosed herein and methods of using the same are also provided.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The present invention relates to an antibody specifically binding to a tryptophanyl-tRNA synthetase (WRS) protein and, more specifically, to: an antibody, or a fragment of the antibody, specifically binding to a polypeptide of an amino acid sequence represented by SEQ ID NO: 2 in a WRS protein; a polynucleotide encoding the antibody and a vector comprising same; a cell transformed using same; and a use thereof.